1418033-25-6

Basic information

• Product Name: LMK-235
• Synonyms: LMK-235;N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethyl-benzamide;N-[[6-(Hydroxyamino)-6-oxohexyl]oxy]-3,5-dimethylbenzamide LMK-235
• CAS NO: 1418033-25-6
• Molecular Formula: C₁₅H₂₂N₂O₄
• Molecular Weight: 294.34618
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 1418033-25-6.mol
• Article Data: 1

Chemical Properties

• Appearance: white to beige/
• Density: 1.155±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble20mg/mL, clear
• PKA: 9.46±0.20(Predicted)
• CAS DataBase Reference: LMK-235(CAS DataBase Reference)
• NIST Chemistry Reference: LMK-235(1418033-25-6)
• EPA Substance Registry System: LMK-235(1418033-25-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 1418033-25-6(Hazardous Substances Data)

Usage

Description

LMK-235 is a histone deacetylase (HDAC) inhibitor that selectively targets HDACs 4 and 5, displaying enhanced cytotoxic effects against various human cancer cell lines. It is known for its ability to inhibit the growth of the malarial parasite P. falciparum at multiple life cycle stages at nanomolar concentrations.

Uses

Used in Pharmaceutical Industry:
LMK-235 is used as an HDAC inhibitor for its selective targeting of HDACs 4 and 5, which results in enhanced cytotoxic effects against human cancer cell lines such as A2780, Cal27, Kyse510, and MDA-MB231.
Used in Anticancer Applications:
LMK-235 is used as an anticancer agent due to its ability to inhibit the growth of cancer cells and its potential synergistic effects when combined with conventional chemotherapeutic drugs.
Used in Malaria Treatment:
LMK-235 is used as an antimalarial agent for its ability to inhibit the growth of the malarial parasite P. falciparum at multiple life cycle stages at nanomolar concentrations.

Biochem/physiol Actions

LMK-235 induces the differentiation of odontoblasts in dental pulp cells. It plays an important role in the regeneration of dental tissue.

Upstream product

• 78277-26-6 benzyl 6-bromohexanoate 
• 1418033-00-7 N-((6-((benzyloxy)amino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide 
• 1418032-61-7 benzyl 6-(1,3-dioxoisoindolin-2-yloxy)hexanoate 
• 1101114-27-5 6-(1,3-dioxo-1,3-dihydroisoindol-2-yloxy)hexanoic acid 

Relevant articles and documents

Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells

The synthesis and biological evaluation of new potent hydroxamate-based HDAC inhibitors with a novel alkoxyamide connecting unit linker region are described. Biological evaluation includes MTT and cellular HDAC assays on sensitive and chemoresistant cancer cell lines as well as HDAC profiling of selected compounds. Compound 19i (LMK235) (N-((6-(hydroxyamino)-6-oxohexyl)oxy)- 3,5-dimethylbenzamide) showed similar effects compared to vorinostat on inhibition of cellular HDACs in a pan-HDAC assay but enhanced cytotoxic effects against the human cancer cell lines A2780, Cal27, Kyse510, and MDA-MB231. Subsequent HDAC profiling yielded a novel HDAC isoform selectivity profile of 19i in comparison to vorinostat or trichostatin A (TSA). 19i shows nanomolar inhibition of HDAC4 and HDAC5, whereas vorinostat and TSA inhibit HDAC4 and HDAC5 in the higher micromolar range.